Ceterix Announces Issuance of Two Key Patents for Minimally Invasive Orthopaedic Suturing

MENLO PARK, California – August 6, 2013 – Ceterix® Orthopaedics, Inc., a developer of novel surgical tools that expand and improve minimally invasive tissue procedures, today announced the issuance of two key patents for the company’s proprietary technology used in meniscal tear and other soft tissue injury procedures.1,2

Ceterix’s patents describe unique methods and designs that allow surgeons to pass suture through soft tissue in very tight joint compartments arthroscopically. These inventions enable orthopaedic surgeons to address complex knee, hip, and shoulder injuries that have not been amenable to repair in the past. One aspect of the technology allows the placement of a circumferential compression stitch in the knee meniscus, which is tightly surrounded by critical structures such as nerves, arteries and cartilage. The technology can also be utilized in minimally invasive hip and shoulder procedures.

“The issuance of these patents validates the innovative nature of our approach for addressing meniscus tears and for other soft tissue procedures,” said John McCutcheon, president and CEO of Ceterix. “Patents are critical to the success of a medical-device startup, and we are very pleased to have these two important patents issued so early in the company’s existence. Because we were given Track One prioritized examination status – part of the new U.S. patent program for expedited review initiated in 2011 – these patents were issued in just over one year, rather than the four or five years it might have taken previously.”

Arthroscopic surgery is a minimally invasive surgical procedure performed by an orthopaedic physician in which a damaged joint is treated through small incisions with specialized tools under the guidance of a tiny camera called an arthroscope. Meniscus surgeries are the most common arthroscopic surgery in the United States, with roughly one million procedures annually.

About Ceterix Orthopaedics

Ceterix® Orthopaedics develops surgical tools that expand and improve what is possible for physicians who treat soft tissue injuries such as meniscus tears, hip and shoulder labrum tears, and rotator cuff tears. Founded in 2010 with the vision of improving outcomes of arthroscopic procedures, Ceterix’s novel suture passing device enables surgeons to place suture patterns that were previously only possible in open procedures, or not at all. The company is based in Menlo Park, Calif. and is backed by investors Novo Ventures, Versant Ventures and 5AM Ventures. For more information, please visit http://www.ceterix.com/cet/.

1. US 8,449,533 B2, Devices, Systems, and Methods for Meniscus Repair
2. US 8,465,505 B2, Suture Passer Devices and Methods

Media Contact:

Nicole Osmer

« Go Back